Core Viewpoint - Wanbangde (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has received approval from the Medical Ethics Committee of Wenzhou Medical University Second Affiliated Hospital and Wenzhou Medical University Affiliated Yuying Children's Hospital to conduct Phase I clinical trials for its new drug WP107, which is aimed at treating myasthenia gravis [1] Group 1 - Wanbangde's new drug WP107 is specifically designed for the treatment of myasthenia gravis [1] - The approval for the clinical trial was granted by two medical institutions affiliated with Wenzhou Medical University [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002082 证券简称：万邦德 公告编号：2025-067 万邦德医药控股集团股份有限公司关于控股股东部分股份质押及解除质押的公告 公司控股股东、实际控制人及其一致行动人保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 四、控股股东及其一致行动人股份质押情况 1.公司控股股东及其一致行动人本次质押与上市公司生产经营需求无关。 万邦德医药控股集团股份有限公司（以下简称"公司"）近日收到公司控股股东万邦德集团有限公司（以 下简称"万邦德集团"）的通知，获悉其所持有公司的部分股份办理了质押及解除质押手续，具体事项如 下： 一、股东股份质押基本情况 ■ 二、股东股份解除质押基本情况 ■ 三、股东股份累计质押情况 截至本公告披露日，万邦德集团及其一致行动人所持质押股份情况如下： ■ 2.公司实际控制人庄惠女士质押的691万股于半年内到期，除此之外，控股股东及实际控制人不存在未 来半年内或一年内到期的质押股份。 3.公司控股股东及其 ...

Core Viewpoint - The announcement indicates that the controlling shareholder, Wanbond Group, has pledged 10.23 million shares to Bilifu (Shenzhen) Commercial Factoring Co., Ltd. for financing guarantees, which represents 5.80% of its holdings and 1.67% of the total share capital [1] Summary by Relevant Sections Share Pledge Details - Wanbond Group has pledged 10.23 million shares, which is 5.80% of its holdings and 1.67% of the total share capital, for financing guarantees [1] - The pledge is set to be released on December 25, 2025 [1] Shareholding Structure - As of the announcement date, Wanbond Group and its concerted parties hold a total of 248,747,078 shares, accounting for 40.67% of the total share capital [1] - The total number of pledged shares by the controlling shareholder and its concerted parties amounts to 198,199,616 shares, which is 79.68% of their holdings and 32.40% of the total share capital [1] Impact Assessment - The pledge of shares by the controlling shareholder and actual controller is stated to have no substantial impact on the company [1]

证券代码：002082 证券简称：万邦德 公告编号：2025-067 万邦德医药控股集团股份有限公司 关于控股股东部分股份质押及解除质押的公告 万邦德医药控股集团股份有限公司（以下简称"公司"）近日收到公司控股 股东万邦德集团有限公司（以下简称"万邦德集团"）的通知，获悉其所持有公 司的部分股份办理了质押及解除质押手续，具体事项如下： 二、股东股份解除质押基本情况 | 股东名 称 | 是否为控股 股东或第一 大股东及其 | 本次解除质 押股份数量 | 占其所 持股份 | 占公司总 股本比例 | 质押起 始日 | 质押解 除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行动人 | (股) | 比例（%） | （%） | | | | | 万邦德 | | | | | 2025 年 | 2025 年 | 比利夫（深圳） | | 集团有 | 是 | 10,230,000 | 5.80 | 1.67 | 12 月 19 | 12 月 25 | 商业保理有限 | | 限公司 | | | | | 日 | 日 | 公司 | 三、股东股份累计质 ...

Market Performance - The Chinese medicine sector rose by 0.35% on December 25, with Wanbangde leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Gainers in Chinese Medicine Sector - Wanbangde (002082) closed at 13.42, up 10.00% with a trading volume of 221,500 shares and a transaction value of 286 million yuan [1] - ST Changyao (300391) closed at 1.53, up 5.52% with a trading volume of 469,000 shares and a transaction value of 71.61 million yuan [1] - Huasen Pharmaceutical (002907) closed at 15.57, up 4.01% with a trading volume of 62,100 shares and a transaction value of 96.15 million yuan [1] Market Trends and Capital Flow - The Chinese medicine sector experienced a net outflow of 130 million yuan from institutional investors, while retail investors saw a net inflow of 163 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Wanbangde had a net inflow of 30.98 million yuan from institutional investors, but a net outflow of 30.35 million yuan from retail investors [3] - Jiaying Pharmaceutical (002198) saw a net inflow of 16.25 million yuan from institutional investors, while retail investors had a net outflow of 9.67 million yuan [3] - Kangmei Pharmaceutical (600518) experienced a net inflow of 15.73 million yuan from institutional investors, with retail investors withdrawing 4.15 million yuan [3]

Market Overview - The Shanghai Composite Index rose by 0.53% on December 24, with 26 out of the 28 sectors experiencing gains, led by the defense and electronics sectors, which increased by 2.88% and 2.12% respectively [1] - The pharmaceutical and biological sector saw a modest increase of 0.24% [1] - The agriculture, forestry, animal husbandry, and fishery sectors, along with coal, were the worst performers, declining by 0.85% and 0.70% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets reached 10.37 billion yuan, with 17 sectors experiencing net inflows [1] - The electronics sector had the highest net inflow, totaling 8.68 billion yuan, coinciding with its 2.12% increase [1] - The power equipment sector also performed well, with a 1.03% increase and a net inflow of 3.76 billion yuan [1] - Conversely, 14 sectors experienced net outflows, with the non-ferrous metals sector leading with a net outflow of 1.635 billion yuan, followed by the basic chemicals sector with 1.212 billion yuan [1] Pharmaceutical and Biological Sector - The pharmaceutical and biological sector increased by 0.24%, but faced a net outflow of 1.141 billion yuan [2] - Out of 479 stocks in this sector, 320 rose while 134 fell, with one stock hitting the daily limit down [2] - The top three stocks with significant net inflows included C Jianxin with 690 million yuan, followed by Hanyu Pharmaceutical and Innovation Medical with 134 million yuan and 68.69 million yuan respectively [2] - The sector's outflow leaders included Hainan Haiyao with a net outflow of 280 million yuan, followed by Heng Rui Pharmaceutical and Luyan Pharmaceutical with 180 million yuan and 136.53 million yuan respectively [4]

Core Viewpoint - The announcement of the largest Alzheimer's disease registration study in China has been made by Wanbangde, focusing on the clinical trial of its new drug, Huperzine A controlled-release tablets, for treating mild to moderate Alzheimer's disease [1][3]. Group 1: Drug Development and Clinical Trials - Wanbangde's subsidiary has completed the enrollment of 50 subjects for the Phase II/III clinical trial of Huperzine A controlled-release tablets, which received approval for the key registration trial in July [1][2]. - The drug is designed to improve cognitive function and has shown potential in preclinical studies to slow the progression of Alzheimer's disease, with benefits including the reduction of β-amyloid protein, anti-inflammatory effects, and neuroprotection [2][3]. - The controlled-release technology used in the formulation allows for a smoother drug release profile, enhancing patient compliance and safety by enabling once-daily dosing [2]. Group 2: Company Background and Market Position - Wanbangde is based in Taizhou, Zhejiang, a significant hub for raw material drug production in China, and focuses on the pharmaceutical manufacturing and healthcare industry, covering various therapeutic areas including cardiovascular, neurological, respiratory, digestive, and mental health [1]. - The company has established a reputation in the neurological treatment field, with its Huperzine A injection recognized as a first-line medication for memory disorders caused by dementia and other brain conditions [1][2].

Core Viewpoint - Wanbangde (002082.SZ) announced the completion of enrollment for 50 subjects in the key Phase II/III clinical trial of its new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease dementia [1] Group 1: Company Developments - Wanbangde's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., is conducting the clinical trial for Huperzine A, which is classified as a Class 2 new drug [1] - The drug is a cholinesterase inhibitor designed to improve cognitive function and has shown potential in preclinical studies to delay the progression of Alzheimer's disease [1] Group 2: Drug Characteristics and Potential - Huperzine A exhibits a range of benefits, including the reduction of beta-amyloid protein, anti-inflammatory effects, antioxidant stress response, and neuroprotection [1] - The drug is expected to become a broad-spectrum treatment for Alzheimer's disease dementia [1]

完成 50 例受试者入组的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团有限公司的 2.2 类新药石杉碱甲控释片用于治疗轻、中度阿尔茨海默病 型痴呆的 II/III 期关键注册临床试验，于近日完成 50 例受试者入组。现将相关 情况公告如下： 一、产品基本情况 名称：石杉碱甲控释片 英文名称：Huperzine A Controlled-Release Tablets 证券代码：002082 证券简称：万邦德 公告编号：2025-066 万邦德医药控股集团股份有限公司 关于石杉碱甲控释片 II/III 期临床试验 临床研究阶段：Ⅱ/Ⅲ期 临床研究组长单位：首都医科大学宣武医院 石杉碱甲是用于改善认知功能的胆碱酯酶抑制剂，临床前研究展现出延缓阿 尔茨海默病疾病进展的潜力及广泛的综合获益，包括对β淀粉样蛋白的降低作用， 抗炎、抗氧化应激以及神经元保护作用，有望成为具有广谱抗阿尔茨海默病型痴 呆的药物。 石杉碱甲控释片是公司自主研发的用于治疗轻、中度阿尔茨海默病型痴呆的 2.2 类新 ...

Group 1 - The core announcement is that Wanbangde (002082) has completed the enrollment of 50 subjects for its Phase II/III pivotal registration clinical trial of the new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease [1] Group 2 - The drug is classified as a Class 2 new drug, indicating its potential significance in the pharmaceutical market [1] - The completion of subject enrollment marks a critical step in the clinical trial process, which is essential for regulatory approval [1] - The trial's focus on Alzheimer's disease highlights the growing demand for effective treatments in this therapeutic area, reflecting broader industry trends [1]